| Literature DB >> 35292094 |
Chika Sato1,2, Yoshi-Ichiro Kamijo3,4,5, Yuta Sakurai1, Shohei Araki1, Yuki Sakata1,2, Ayana Ishigame1, Kota Murai1,2, Izumi Yoshioka1, Fumihiro Tajima1,2,6.
Abstract
BACKGROUND: Blood volume (BV) is a critical factor for physical endurance in chronic stroke patients, while hypervolemia can worsen hypertension in these patients. This prospective study assessed whether rehabilitation combined with protein supplementation immediately after each exercise for 3 weeks would improve plasma volume (PV) and BV as well as physical endurance without worsening hypertension.Entities:
Keywords: Blood volume; Cerebrovascular disorders; Dietary supplements; PROr; Physical endurance
Year: 2022 PMID: 35292094 PMCID: PMC8922777 DOI: 10.1186/s13102-022-00429-x
Source DB: PubMed Journal: BMC Sports Sci Med Rehabil ISSN: 2052-1847
Fig. 1CONSORT Flow Diagram. We recruited 23 patients, who were admitted to the Nachi-Katsuura Balneologic Town Hospital between June 2017 and December 2018. Two patients refused their participation. Six patients withdrew their consent after the pre-intervention measurements. Fifteen patients were allocated into the intervention (PG; n = 8) and the control groups (CG; n = 7). One patient in the intervention group discontinued intervention due to lost motivation. Each one of both groups performed both trials, after a wash-out period of 5 or 6 months. Finally, 8 patients in each group completed this trial
Fig. 2Study protocol. Each patient received in-hospital 11-h rehabilitation program per week for 3 weeks. Each rehabilitation session lasted 1 h, the 1st one was conducted in the morning and another in the afternoon on 5 weekdays, and one session was done on Saturday morning. Treadmill; walking on treadmill (WEBG3300, Reha-Tread G, Senoh Corporation, Chiba, Japan) at a speed adjusted according to each patient. Stepping the stairs; climbing up and down the stairs in the hospital. Hand cycling ergometer; cycling upper body ergometer (WBK284740H, Rehab Trainer 881E, Monark Exercise AB, Sverige, Sweden) with their hands at wattage adjusted according to each patient. Standing up repetition; standing up from a chair, sitting down and repeating. The Borg’s scale of each patient’s program was recorded. Patients of the intervention group received protein-rich jelly while those of the control group received protein-free jelly within 30 min after the rehabilitation session. Physical fitness tests were performed in the evening of the day before starting the rehabilitation program and the last day of 3-week program. Blood samples were drawn and plasma volume was measured during 7:30–8:00 am before breakfast on the same days as above. *, blood pressure and pulse rate were checked. CPX, Cardiopulmonary exercise testing.
Fig. 3The Borg’s scale during intervention in the Black dot, PG; White dot, CG. To determine differences in the Borg’s scale during intervention between groups, unpaired t-test was applied at each time point during day 1 to 18. Because of lacks of data at day 1, 8, 12, 17 and 18, numbers of data at these days are shown in parentheses. Differences were considered statistically significant at P < 0.05. Statistical evaluations were performed using SPSS (version 24.0; IBM, Chicago, IL). Values are represented as mean (SD) unless otherwise stated. All participants performed rehabilitation for 33 sessions
Fig. 4Measurement of knee extension strength with hand-held dynamometer. The patients sat on a chair and their hips and knees flexed 90 degrees [25–27]. An examiner put the dynamometer at 20 cm distal to their knee joint. Patients were reported to extend the knee joint as possible as they could
Characteristics of the participants
| PG (n = 8) | CG (n = 8) | ||
|---|---|---|---|
| Age, years | 76.1 (5.3) | 75.6 (6.9) | 0.873 |
| Sex, women/men | 5/3 | 3/5 | 0.317 |
| Height, cm | 153.4 (4.5) | 157.4 (8.9) | 0.269 |
| BMI, kg/m2 | 23.11 (1.68) | 23.10 (3.10) | 0.993 |
| Disease type, haemorrhage/infarction | 3/5 | 3/5 | 1.000 |
| Paralyzed side, right/left | 4/4 | 3/5 | 0.614 |
| Use of walking brace | 1 | 1 | 1.000 |
| Use of cane | 4 | 4 | 1.000 |
| Time since onset, months | 42 (33) | 66 (38) | 0.196 |
| Fugl-Meyer Assessment (total 226) ¶ | 210.7 (10.8) | 209.3 (14.3) | 0.828 |
| Motor function score of FMA (total 100) ¶ | 90 (5.5) | 92.4 (3.6) | 0.854 |
Values are shown as means (SD) and numbers of each relevant item for a total of 16 ambulatory patients with chronic cerebrovascular disease. PG, intervention group, in which participants ingested high protein jelly within 30 min after each exercise session (n = 8; containing 10 g protein); CG, control group, intaking protein-free jelly (n = 8); Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index [28]. FMA, an index of physical dysfunction in patients with hemiplegia, consisted of assessments for motor functions of the upper (66) and lower extremities (34), sensory (24), balance (14), ranges of motion (44), and joint pain during exercise (44), with a total score of 226 in 7 and 8 participants in PG and CG, respectively ¶. Regarding motor function score of FMA, which consists of upper and lower extremities, total of which is 100, Duncan et al. classified as follows: 0–35, severe; 36–55, moderately severe; 56–79, moderate; and 80 or greater as mild [53]. P values of the unpaired t-test or χ2 test are shown
Diet during intervention
| PG (n = 8) | CG (n = 8) | ||
|---|---|---|---|
| Total energy, kcal/kg BM/day | 26.01 (5.89) | 26.01 (6.47) | 0.999 |
| Proteins, g/kg BM/day | 1.13 (0.27) | 1.09 (0.23) | 0.749 |
| Carbohydrates, g/kg BM/day | 3.73 (0.84) | 3.69 (0.89) | 0.935 |
| Lipids, g/kg BM/day | 0.70 (0.21) | 0.74 (0.22) | 0.687 |
| Salt, mg/kg BM/day | 108.40 (24.35) | 103.31 (26.47) | 0.695 |
The diet was provided every day for all patients. Values are shown as the mean (SD)
P values are for the unpaired t-test
Medication content in both groups
| Types of medicines | PG (n = 8) | CG (n = 8) | |
|---|---|---|---|
| Antihypertensives | |||
| Calcium blocker | 3 | 5 | 0.317 |
| α blocker | 0 | 1 | 0.302 |
| β blocker | 1 | 1 | 1.000 |
| ARB | 3 | 3 | 1.000 |
| Diuretics | 2 | 1 | 0.522 |
| Antithromboembolism | |||
| Anticoagulants | 2 | 1 | 0.522 |
| Antiplatelet agents | 5 | 6 | 0.590 |
| Antithyperlipidemia (HMG-CoA reductase inhibitor) | |||
| 5 | 5 | 1.000 | |
| Antidiabetic drug | |||
| 2 | 0 | 0.131 | |
| Osteoporosis drug (an analogue of vitamin D) | |||
| 5 | 4 | 0.614 | |
| Analgesics | |||
| NSAIDs | 0 | 2 | 0.131 |
| Pregabalin | 2 | 2 | 1.000 |
| Antidepressant | |||
| SNRI | 0 | 1 | 0.302 |
| SSRI | 1 | 1 | 1.000 |
| Nonbenzodiazepine | 1 | 1 | 1.000 |
| Benzodiazepine | 1 | 3 | 0.248 |
| Gastric secretion inhibitor/ mucosal defense | |||
| Proton pump inhibitor | 6 | 3 | 0.131 |
| H2 receptor antagonist | 0 | 2 | 0.131 |
| Gastric mucosal defense | 0 | 3 | 0.055 |
| Cardiorespiratory disease drugs | |||
| Bronchodilator (β agonist) | 0 | 1 | 0.302 |
| Antitussive | 0 | 1 | 0.302 |
| Anti-allergic (antihistamine) | 1 | 0 | 0.302 |
| Digitalis | 1 | 0 | 0.302 |
| Urologic disease drugs | |||
| Anticholinergic agent | 1 | 0 | 0.302 |
| β3 agonist | 0 | 1 | 0.302 |
| Urinary tract antispasmodic | 0 | 1 | 0.302 |
| Others | |||
| Laxative | 3 | 3 | 1.000 |
| Thyroid hormone preparation | 1 | 0 | 0.302 |
| Antihyperuricemic | 1 | 1 | 1.000 |
| Acetylcholinesterase inhibitor | 1 | 1 | 1.000 |
The numbers of medications in the intervention (PG) and control groups (CG) are shown
ARB, angiotensin II receptor blocker; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; NSAIDs, non-steroidal anti-inflammatory drug; SNRI, serotonin-noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor
The P values of the χ2 test were described
Haemoglobin concentration, haematocrit, blood sugar, and serum profiles before and after the intervention
| Measurements | PG (n = 8) | CG (n = 8) | |||
|---|---|---|---|---|---|
| Before | After | Before | After | Time Group | |
| [Hb], g/dL | 12.6 (1.9) | 12.7 (2.2) | 13.0 (1.7) | 12.9 (1.9) | 0.781 0.753 0.734 |
| Haematocrit, % | 37.3 (5.6) | 37.9 (5.2) | 38.9 (4.5) | 39.0 (4.7) | 0.415 0.584 0.582 |
| [Albumin]s, g/dL | 4.1 (0.4) | 4.0 (0.2) | 4.4 (0.2) | 4.2 (0.3) | 0.133 0.136 0.862 |
| [Creatinine]s, mg/dL | 0.85 (0.27) | 0.87 (0.21) | 0.888 | ||
| C-reactive protein, mg/dL | 0.1 (0.2) | 0.3 (0.2) | 0.204 | ||
| Blood sugar, mg/dL | 121.8 (23.5) | 119.0 (21.0) | 0.809 | ||
| [Total cholesterol]s, mg/dL | 184.0 (32.8) | 188.0 (25.7) | 0.790 | ||
| [Triglycerides]s, mg/dL | 210.1 (77.0) | 204.0 (132.0) | 0.911 | ||
Data are median values (SD) in the intervention (PG) and control groups (CG)
[Hb], haemoglobin concentration; []s, serum concentration of each relevant item. Ht, haematocrit, and albumin levels were assessed by two-way repeated measures ANOVA
P values of the effects of group, time, and interaction group and time are shown. The P values of the other samples compared by the unpaired t-test are also shown
Fig. 5Plasma (PV; panel a) and blood volumes (BV; panel b) before (before) and after the intervention (after) in the intervention (PG; n = 8) and the control groups (CG; n = 8). PG in left, CG in right. Values are shown as means ± SD. †, significant differences from “Before” at the level of P < 0.05
Body weight, cardiovascular responses, physical fitness, and walking performance before and after 3-week rehabilitation in both groups
| Measurements | PG (n = 8) | CG (n = 8) | |||
|---|---|---|---|---|---|
| Before | After | Before | After | Time Group | |
| Body weight, kg | 54.5 (6.5) | 52.9 (6.2)† | 57.5 (10.8) | 55.4 (9.5)† | 0.004 0.532 0.639 |
| Systolic blood pressure, mmHg | 119.8 (17.6) | 121.9 (17.6) | 128.3 (11.3) | 120.9 (10.8) | 0.401 0.584 0.139 |
| Diastolic blood pressure, mmHg | 82.0 (12.2) | 81.1 (15.3) | 88.5 (7.9) | 76.3 (11.5) | 0.046 0.878 0.079 |
| Pulse pressure, mmHg | 37.8 (9.4) | 40.8 (12.7) | 39.8 (10.0) | 44.6 (13.7) | 0.274 0.538 0.790 |
| Mean arterial pressure, mmHg | 94.6 (13.5) | 94.7 (15.0) | 101.8 (7.8) | 91.1 (9.2) † | 0.052 0.737 0.052 |
| Rate-pressure product | 8713 (1780) | 8864 (1781) | 9749 (1583) | 8798 (1519) † | 0.129 0.553 0.043 |
| Heart rate, beats/min | |||||
| Rest | 72.6 (8.6) | 72.8 (10.0) | 76.6 (14.4) | 72.8 (10.0) | 0.307 0.706 0.277 |
| Peak | 125 (21) | 127 (19) | 127 (18) | 125 (19) ¶ | 0.976 0.978 0.694 |
| VO2, mL/kg/min | |||||
| Rest | 4.8 (1.2) | 4.4 (0.9) | 5.9 (1.3) | 5.2 (1.3) | 0.049 0.109 0.514 |
| Peak | 17.7 (3.9) | 19.3 (2.2)† | 19.6 (4.0) | 21.2 (4.4)† | 0.035 0.276 0.994 |
| VO2, mL/min | |||||
| Peak | 956.1 (211.1) | 1022.0 (182.0) | 1134.8 (335.8) | 1187.7 (340.2) | 0.136 0.217 0.866 |
| Knee-extensor strength, Nm | |||||
| Paralyzed | 35.9 (13.7) | 39.6 (13.8)† | 33.6 (6.7) | 36.8 (5.7)† | 0.001 0.636 0.798 |
| Non-paralyzed | 48.2 (10.2) | 48.9 (10.6) | 43.9 (8.0) | 44.2 (6.2) | 0.532 0.322 0.826 |
| 6MWD, m | 288 (106) | 342 (108)† | 281 (110) | 296 (117) | 0.001 0.641 0.037 |
| 10MWS, m/sec | |||||
| Optimum | 0.84 (0.32) | 0.95 (0.31)† | 0.78 (0.25) | 0.85 (0.33) | 0.019 0.597 0.530 |
| Maximum | 1.12 (0.42) | 1.26 (0.40) | 1.08 (0.49) | 1.09 (0.55) | 0.116 0.116 0.181 |
Values are shown as mean (SD) in the intervention (PG) and control groups (CG). Systolic (SBP) and diastolic blood pressure (DBP) were measured at rest before cardiopulmonary exercise testing. The heart rate at peak was recorded during cardiopulmonary exercise testing in 8 and 7 participants (¶) in PG and CG, respectively. The pulse pressure was calculated as SBP – DBP. The mean arterial pressure was calculated as DBP + (SBP − DBP)/3. The rate-pressure product was calculated as the heart rate × SBP. VO2, oxygen consumption rate; 6MWD, 6-min walking distance; 10MWS, 10-m walking speed; †, compared with the baseline before the onset of rehabilitation program at the level of P < 0.05, as determined by the paired t-test
P values of the effects of group and time and interaction group and time from two-way ANOVA repeated measurement are shown
Effects of 3-week rehabilitation and supplements on plasma concentrations of cortisol, catecholamines and aldosterone
| PG (n = 8) | CG (n = 8) | ||||
|---|---|---|---|---|---|
| Before | After | Before | After | Time Group | |
| [Cortisol]p, μg/dL | 12.27 (4.84) | 13.02 (2.95) | 10.30 (2.58) | 10.37 (1.79) | 0.581 0.132 0.674 |
| [Adrenaline]p, pg/mL | 26.75 (13.22) | 28.25 (11.91) | 36.13 (17.30) | 38.50 (25.02) | 0.479 0.262 0.872 |
| [Noradrenaline]p, pg/mL | 386.38 (259.28) | 460.63 (273.52) | 512.25 (363.39) | 560.38 (342.37) | 0.134 0.469 0.739 |
| [Dopamine]p, pg/mL | 8.50 (4.07) | 12.75 (5.20) | 16.63 (9.80) | 16.63 (7.69) | 0.264 0.067 0.264 |
| [Aldosterone]p, pg/mLa | 78.7 (38.4) | 60.2 (24.5)† | 47.98 (33.1) | 46.25 (17.63) | 0.046 0.204 0.089 |
Plasma concentrations of cortisol ([cortisol]p), adrenaline ([adrenaline]p), noradrenaline ([noradrenaline]p), dopamine ([dopamine]p), and aldosterone ([aldosterone]p) are shown as means (SD) in the intervention (PG) and the control group (CG)
P values of the effects of group and time and interaction group and time from two-way ANOVA repeated measurement are shown. †, compared between before and after the onset of rehabilitation program at the level of P < 0.05
an = 6 because of the lack of samples